Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment

Author(s): Zhiwei Wang, Lixin Wan, Jiateng Zhong, Hiroyuki Inuzuka, Pengda Liu, Fazlul H. Sarkar, Wenyi Wei

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 18 , 2013

Become EABM
Become Reviewer
Call for Editor


The Anaphase Promoting Complex (APC) has been characterized to play pivotal roles in regulating the timely cell cycle progression by forming two functionally distinct E3 ubiquitin ligase sub-complexes, APCCdc20 and APCCdh1. Interestingly, recent studies have shown that Cdh1 is functioning as a tumor suppressor whereas Cdc20 may function as an oncoprotein to promote the development and progression of human cancers. In this review, we will discuss the physiological role of Cdc20 and its downstream substrates in vitro and in the transgenic mouse model reminiscent of the pathogenesis of human cancers. Furthermore, we summarize recent findings to indicate that Cdc20 may represent a promising therapeutic target, thus development of Cdc20 inhibitors could be useful for achieving better treatment outcome of cancer patients.

Keywords: Cancer, Cdc20, cell growth, oncogene, ubiquitination, therapy.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 31 March, 2013
Page: [3210 - 3214]
Pages: 5
DOI: 10.2174/1381612811319180005

Article Metrics

PDF: 80